- Home
- ALKS vs GH Comparison
ALKS vs GH Comparison
Compare ALKS & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALKS
- GH
- Stock Information
- Founded
- ALKS 1987
- GH 2011
- Country
- ALKS Ireland
- GH United States
- Employees
- ALKS N/A
- GH N/A
- Industry
- ALKS Biotechnology: Pharmaceutical Preparations
- GH Medical Specialities
- Sector
- ALKS Health Care
- GH Health Care
- Exchange
- ALKS Nasdaq
- GH Nasdaq
- Market Cap
- ALKS 5.0B
- GH 4.9B
- IPO Year
- ALKS 1991
- GH 2018
- Fundamental
- Price
- ALKS $30.70
- GH $93.02
- Analyst Decision
- ALKS Strong Buy
- GH Strong Buy
- Analyst Count
- ALKS 13
- GH 22
- Target Price
- ALKS $42.31
- GH $74.32
- AVG Volume (30 Days)
- ALKS 2.3M
- GH 2.7M
- Earning Date
- ALKS 10-28-2025
- GH 10-29-2025
- Dividend Yield
- ALKS N/A
- GH N/A
- EPS Growth
- ALKS 2.44
- GH N/A
- EPS
- ALKS 2.02
- GH N/A
- Revenue
- ALKS $1,521,338,000.00
- GH $902,569,000.00
- Revenue This Year
- ALKS N/A
- GH $28.28
- Revenue Next Year
- ALKS $1.59
- GH $23.00
- P/E Ratio
- ALKS $15.25
- GH N/A
- Revenue Growth
- ALKS 1.08
- GH 30.38
- 52 Week Low
- ALKS $25.17
- GH $21.85
- 52 Week High
- ALKS $36.45
- GH $95.88
- Technical
- Relative Strength Index (RSI)
- ALKS 52.10
- GH 81.95
- Support Level
- ALKS $28.47
- GH $68.02
- Resistance Level
- ALKS $32.11
- GH $95.88
- Average True Range (ATR)
- ALKS 1.30
- GH 3.64
- MACD
- ALKS -0.12
- GH 2.40
- Stochastic Oscillator
- ALKS 56.74
- GH 91.80
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.